Dahiya R, Itzkowitz S H, Byrd J C, Kim Y S
Gastrointestinal Research Laboratory, Veterans Administration Medical Center, San Francisco, California.
Cancer Res. 1989 Aug 15;49(16):4550-6.
The synthesis of blood group ABH antigens is under genetic control, where the primary gene products are glycosyltransferases. Several studies have demonstrated cancer-associated alterations in ABH antigen expression in human colon cancer tissues. However, the mechanism(s) responsible for these alterations has not been elucidated. Therefore, experiments were conducted using nine established colon cancer cell lines (four type O, three type A, and two type B) to examine ABH antigen expression by immunocytochemistry and correlate this with activities of ABH biosynthetic (glycosyltransferase) and degradative (glycosidase) enzymes. The products of the glycosyltransferase enzymes were characterized by high performance liquid chromatography and paper chromatography, and substrate affinities (apparent Km values) of the cancer cell-derived glycosyltransferases were analyzed. The present data demonstrate: (a) all cell lines except H-498 (blood type A) expressed the appropriate ABH glycosyltransferase as well as all three glycosidases; (b) product characterization and substrate dependence experiments suggested that the cancer cell-derived ABH glycosyltransferase enzymes had properties that were similar to those of the ABH enzymes in human serum; (c) H-498 cells exhibited A antigen deletion with accumulation of H precursor substance, most likely due to insufficient A transferase activity; (d) SW1417 cells (blood type B) demonstrated B antigen deletion without precursor accumulation, despite adequate levels of B transferase and low alpha-galactosidase activity; and (e) weak incompatible A antigen expression occurred in LoVo (type B) and SW1116 (type O) cells, and weak incompatible B antigen expression occurred in H-498 (type A) and SW1116 cells. However, since these cells lacked incompatible A or B transferase activity, these incompatible antigens are probably not the true A or B antigens. Thus, the colon cancer cell lines used in this study exhibit all of the ABH alterations previously described in colon cancer tissues and appear to be useful experimental models for studying the molecular events involved in cancer-associated ABH expression.
ABH血型抗原的合成受遗传控制,其主要基因产物是糖基转移酶。多项研究已证明人类结肠癌组织中ABH抗原表达存在与癌症相关的改变。然而,导致这些改变的机制尚未阐明。因此,利用九种已建立的结肠癌细胞系(四种O型、三种A型和两种B型)进行实验,通过免疫细胞化学检测ABH抗原表达,并将其与ABH生物合成(糖基转移酶)和降解(糖苷酶)酶的活性相关联。通过高效液相色谱法和纸色谱法对糖基转移酶的产物进行了表征,并分析了癌细胞来源的糖基转移酶的底物亲和力(表观Km值)。目前的数据表明:(a)除H-498(A型血)外,所有细胞系均表达适当的ABH糖基转移酶以及所有三种糖苷酶;(b)产物表征和底物依赖性实验表明,癌细胞来源的ABH糖基转移酶具有与人类血清中ABH酶相似的特性;(c)H-498细胞表现出A抗原缺失,H前体物质积累,最可能的原因是A转移酶活性不足;(d)SW1417细胞(B型血)表现出B抗原缺失且无前体积累,尽管B转移酶水平充足且α-半乳糖苷酶活性较低;(e)LoVo(B型)和SW1116(O型)细胞中出现弱的不兼容A抗原表达,H-498(A型)和SW1116细胞中出现弱的不兼容B抗原表达。然而,由于这些细胞缺乏不兼容的A或B转移酶活性,这些不兼容抗原可能不是真正的A或B抗原。因此,本研究中使用的结肠癌细胞系表现出先前在结肠癌组织中描述的所有ABH改变,似乎是研究与癌症相关的ABH表达所涉及分子事件的有用实验模型。